Cardiol Therapeutics (CRDL) Invested Capital (2020 - 2026)

Cardiol Therapeutics has reported Invested Capital for 7 years, with the latest figure at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 65.81% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (up 65.81% YoY), and the FY2025 full-year result was $14.4 million, down 18.92% from the prior year.
• Invested Capital for Q1 2026 stood at $20.3 million, up from $14.4 million in the prior quarter.
• The five-year high for Invested Capital was $58.2 million in Q1 2022, with the low at $6.9 million in Q3 2025.
• Historically, Invested Capital has averaged $24.9 million across 5 years, with a median of $20.3 million in 2026.
• Annual changes were most pronounced in 2022 — Invested Capital surged 101.16% — and 2024, when it tumbled 71.26%.
• Cardiol Therapeutics' Invested Capital stood at $38.8 million in 2022, then plunged by 46.03% to $20.9 million in 2023, then decreased by 15.4% to $17.7 million in 2024, then decreased by 18.92% to $14.4 million in 2025, then soared by 41.6% to $20.3 million in 2026.
• The last three Invested Capital figures came in at $20.3 million (Q1 2026), $14.4 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.